Acidosis overrides molecular heterogeneity to shape therapeutically targetable metabolic phenotypes in colon cancers
Cancer Letters · 2025
DOI: 10.1016/j.canlet.2025.217512 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Elena Richiardone und 12 weiteren Autor:innen. Beteiligte Einrichtung: Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Avenue Hippocrate 57, B1.57.04, B-12…. Hauptthemen laut MEDLINE: Acidosis, Colonic Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fondazione AIRC per la ricerca sul cancro ETS, FRS-FNRS, WELBIO.
Abstract (Originalsprache)
Colorectal cancer (CRC) represents a prototypical example of a cancer type for which inter- and intra-tumor heterogeneities remain major challenges for the clinical management of patients. Besides genotype-mediated phenotypic alterations, tumor microenvironment (TME) conditions are increasingly recognized to promote intrinsic diversity and phenotypic plasticity and sustain disease progression. In particular, acidosis is a common hallmark of solid tumors, including CRC, and it is known to induce aggressive cancer cell phenotypes. In this study, we report that long-term adaptation to acidic pH conditions is associated with common metabolic alterations, including a glycolysis-to-respiration switch and a higher reliance on the activity of phosphoglycerate dehydrogenase (PHGDH), in CRC cells initially displaying molecularly heterogeneous backgrounds. Pharmacological inhibition of PHGDH activity or mitochondrial respiration induces greater growth-inhibitory effects in acidosis-exposed CRC cells in 2D and 3D culture conditions, and in patient-derived CRC organoids. These data pave the way for drugs targeting the acidic tumor compartment as a "one-size-fits-all" therapeutic approach to delay CRC progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Avenue Hippocrate 57, B1.57.04, B-1200, Brussels, Belgium.
- Centre des Technologies Moléculaires Appliquées (CTMA), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Avenue Hippocrate 54, B-1200, Brussels, Belgium.
- Unit of Molecular Biology, Department of Biology and Pathology of Tumors, Georges-François Leclerc Cancer Center-UNICANCER, 21079, Dijon, France.
- Metabolomics Core Facility, EMBL Heidelberg, Heidelberg, Germany.
- Laboratory of Applied Mass Spectrometry, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium; Metabolomics Core Facility Leuven, Center for Cancer Biology, VIB, Leuven, Belgium.
- Department of Oncology, University of Torino, Candiolo (TO), Italy; Candiolo Cancer Institute - FPO IRCCS, Candiolo (TO), Italy.
Förderung
- Fondazione AIRC per la ricerca sul cancro ETS
- FRS-FNRS
- WELBIO
- Fondation contre le Cancer
Zitieren
APA
Richiardone, E., Giolito, M. V., Al Roumi, R., Ambroise, J., Boidot, R., Drotleff, B., Ghesquière, B., Lupo, B., Trusolino, L., Bardelli, A., Arena, S., Feron, O., & Corbet, C. (2025). Acidosis overrides molecular heterogeneity to shape therapeutically targetable metabolic phenotypes in colon cancers. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217512
Vancouver
Richiardone E, Giolito MV, Al Roumi R, Ambroise J, Boidot R, Drotleff B, et al. Acidosis overrides molecular heterogeneity to shape therapeutically targetable metabolic phenotypes in colon cancers. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217512
BibTeX
@article{Richiardone2025,
author = {Richiardone, Elena and Giolito, Maria Virginia and Al Roumi, Rim and Ambroise, Jérôme and Boidot, Romain and Drotleff, Bernhard and Ghesquière, Bart and Lupo, Barbara and Trusolino, Livio and Bardelli, Alberto and Arena, Sabrina and Feron, Olivier and Corbet, Cyril},
title = {Acidosis overrides molecular heterogeneity to shape therapeutically targetable metabolic phenotypes in colon cancers},
journal = {Cancer Letters},
year = {2025},
doi = {10.1016/j.canlet.2025.217512}
}
EUVIMED